Literature DB >> 11489555

Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions.

M Franco1, G Trapani, A Latrofa, C Tullio, M R Provenzano, M Serra, M Muggironi, G Biggio, G Liso.   

Abstract

Solid dispersions of phenytoin in polyethylene glycol 6000 and polyvinylpyrrolidone K-30 with different drug-to-carrier ratios were prepared by the solvent method with the aim of increasing dissolution rate and bioavailability of the drug. These new formulations were characterized in the solid state by FT-IR spectroscopy, X-ray powder diffraction, and differential scanning calorimetry. Drug solubility and dissolution rate are improved by these formulations, particularly with SDPEG 1/20 and SDPVP 1/20 systems. Storage was found to influence the stability of the solid dispersions. By maximal electroshock test, it was found that the intraperitoneal administration in mice of the SDPEG 1/20 and SDPVP 1/20 systems exhibited anticonvulsant activity similar to diphenylhydantoin sodium salt.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489555     DOI: 10.1016/s0378-5173(01)00751-7

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

1.  Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion.

Authors:  Omaima A Sammour; Mohammed A Hammad; Nagia A Megrab; Ahmed S Zidan
Journal:  AAPS PharmSciTech       Date:  2006-06-16       Impact factor: 3.246

2.  Physicochemical properties of solid dispersions of gliclazide in polyvinylpyrrolidone K90.

Authors:  S Biswal; J Sahoo; P N Murthy
Journal:  AAPS PharmSciTech       Date:  2009-03-25       Impact factor: 3.246

3.  Solid dispersions of imidazolidinedione by PEG and PVP polymers with potential antischistosomal activities.

Authors:  Francimary L Guedes; Boaz G de Oliveira; Marcelo Z Hernandes; Carlos A De Simone; Francisco J B Veiga; Maria do Carmo A de Lima; Ivan R Pitta; Suely L Galdino; Pedro José Rolim Neto
Journal:  AAPS PharmSciTech       Date:  2011-03-01       Impact factor: 3.246

4.  Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice.

Authors:  Naglaa El-Lakkany; Sayed Hassan Seif El-Din; Lamia Heikal
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-03-30       Impact factor: 2.441

5.  Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.

Authors:  S Biswal; J Sahoo; P N Murthy; R P Giradkar; J G Avari
Journal:  AAPS PharmSciTech       Date:  2008-05-06       Impact factor: 3.246

6.  Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug.

Authors:  Usama Farghaly Aly; Hatem Abdel-Monsef Sarhan; Taha F S Ali; Hosny Abd El-Bakey Sharkawy
Journal:  Drug Des Devel Ther       Date:  2020-05-14       Impact factor: 4.162

7.  Improved dissolution and anti-inflammatory activity of ibuprofen-polyethylene glycol 8000 solid dispersion systems.

Authors:  Kenneth C Ofokansi; Franklin C Kenechukwu; Richard O Ezugwu; Anthony A Attama
Journal:  Int J Pharm Investig       Date:  2016 Jul-Sep

8.  A Novel Rheological Method to Assess Drug-Polymer Interactions Regarding Miscibility and Crystallization of Drug in Amorphous Solid Dispersions for Oral Drug Delivery.

Authors:  Georgia Tsakiridou; Christos Reppas; Martin Kuentz; Lida Kalantzi
Journal:  Pharmaceutics       Date:  2019-11-22       Impact factor: 6.321

9.  Formulation development and dissolution rate enhancement of efavirenz by solid dispersion systems.

Authors:  P T Koh; J N Chuah; Meghna Talekar; A Gorajana; S Garg
Journal:  Indian J Pharm Sci       Date:  2013-05       Impact factor: 0.975

10.  Oral Bioavailability Enhancement and Anti-Fatigue Assessment of the Andrographolide Loaded Solid Dispersion.

Authors:  Ching-Chi Yen; Yu-Kai Liang; Chao-Pei Cheng; Mei-Chich Hsu; Yu-Tse Wu
Journal:  Int J Mol Sci       Date:  2020-04-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.